Insight

Reference

·

Primary source

Thailand Diabetes and Pre-Diabetes Prevalence

5.2M diagnosed diabetics, 8.7M pre-diabetes, 62,000 Type-1, 78,000 annual gestational

As ofFY2025 published prevalence·Sources2·Primary

The Ministry of Public Health Thailand Diabetes Registry Annual Report 2025 and IDF Diabetes Atlas (10th edition) Thailand country profile put the Thai adult diabetes prevalence at 5.2 million diagnosed cases, with pre-diabetes (HbA1c 5.7 to 6.4 percent) at roughly 8.7 million people. Type-1 cohort runs approximately 62,000 with NHSO Universal Coverage CGM reimbursement effective Q3 2026. Gestational diabetes annual incidence runs approximately 78,000 pregnancies. The disease cohort anchors the medical-channel CGM TAM while the pre-diabetes cohort drives the consumer-wellness OTC retail expansion through Boots, Watsons, Save Drug pharmacy-corner channels. Thailand ranks among the top 5 ASEAN markets by absolute diabetes burden behind Indonesia and the Philippines.

Download CSV ↓Compare plans →

Figure in context

The Ministry of Public Health Thailand Diabetes Registry Annual Report 2025 and IDF Diabetes Atlas (10th edition) Thailand country profile put the Thai adult diabetes prevalence at 5.2 million diagnosed cases, with pre-diabetes (HbA1c 5.7 to 6.4 percent) at roughly 8.7 million people. Type-1 cohort runs approximately 62,000 with NHSO Universal Coverage CGM reimbursement effective Q3 2026. Gestational diabetes annual incidence runs approximately 78,000 pregnancies. The disease cohort anchors the medical-channel CGM TAM while the pre-diabetes cohort drives the consumer-wellness OTC retail expansion through Boots, Watsons, Save Drug pharmacy-corner channels. Thailand ranks among the top 5 ASEAN markets by absolute diabetes burden behind Indonesia and the Philippines.

The Ministry of Public Health Thailand Diabetes Registry Annual Report 2025 and IDF Diabetes Atlas (10th edition) Thailand country profile put the Thai adult diabetes prevalence at 5.2 million diagnosed cases, with pre-diabetes (HbA1c 5.7 to 6.4 percent) at roughly 8.7 million people. Type-1 cohort runs approximately 62,000 with NHSO Universal Coverage CGM reimbursement effective Q3 2026. Gestational diabetes annual incidence runs approximately 78,000 pregnancies. The disease cohort anchors the medical-channel CGM TAM while the pre-diabetes cohort drives the consumer-wellness OTC retail expansion through Boots, Watsons, Save Drug pharmacy-corner channels. Thailand ranks among the top 5 ASEAN markets by absolute diabetes burden behind Indonesia and the Philippines.

Time scope

FY2025 published prevalence

Source basis

Primary source

Interpretation notes

What this tells you

The Ministry of Public Health Thailand Diabetes Registry Annual Report 2025 and IDF Diabetes Atlas (10th edition) Thailand country profile put the Thai adult diabetes prevalence at 5.2 million diagnosed cases, with pre-diabetes (HbA1c 5.7 to 6.4 percent) at roughly 8.7 million people. Type-1 cohort runs approximately 62,000 with NHSO Universal Coverage CGM reimbursement effective Q3 2026. Gestational diabetes annual incidence runs approximately 78,000 pregnancies. The disease cohort anchors the medical-channel CGM TAM while the pre-diabetes cohort drives the consumer-wellness OTC retail expansion through Boots, Watsons, Save Drug pharmacy-corner channels. Thailand ranks among the top 5 ASEAN markets by absolute diabetes burden behind Indonesia and the Philippines.

What not to do with it

Use the linked report for interpretation and keep basis differences explicit.

Related figures

Adjacent numbers that add context without drowning the value.

2027 forecast
THB 9-15B by 2027 (vs THB 1.4-2.3B 2024)

Thailand CGM and Consumer Wearable Health-Tracker Market Size

Insight derivation from Abbott Form 10-K FY2024, DexCom Form 10-K FY2024, MoPH Diabetes Registry 2025, NHSO benefit schedule, IMARC Global CGM Market Report 2024, IDF Diabetes Atlas Thailand profile

FY2026-FY2027 OTC pricing
THB 1,950-2,800 per 14-day sensor (vs THB 4,800-6,500 prescription baseline)

Thailand CGM Sensor OTC Average Selling Price

Thai FDA Notification B.E. 2569, Abbott FreeStyle Libre 3 Thai product page, Dexcom Stelo product page, Roche Accu-Chek SmartGuide Thai launch, Boots, Watsons, Save Drug pharmacy channel checks

Effective Q3 2026 with full rollout FY2027
~80,000-130,000 sensor units per year (Type-1 plus gestational diabetes)

NHSO Universal Coverage CGM Reimbursement Volume

NHSO Notification on Universal Coverage Benefit Schedule, MoPH Thailand Diabetes Registry Annual Report 2025, Thai Diabetes Association position paper 2026

FY2024 installed base
Apple Watch ~2.1M, Samsung Galaxy Watch ~1.4M, Huawei Watch ~0.8-1.2M

Thailand Premium Smartwatch Installed Base

Insight derivation from Apple Thailand store presence, Samsung Galaxy Watch7 Thai product page, Huawei Watch D Thai launch, IDC Asia Pacific quarterly wearables tracker

FY2026-FY2027 three-channel pricing
NHSO THB 1,650-2,100, OTC THB 1,950-2,800, prescription THB 4,800-6,500

Thailand Abbott FreeStyle Libre 3 Three-Channel Pricing Spread

Abbott FreeStyle Libre 3 Thai product page, Thai FDA Notification B.E. 2569, NHSO benefit-schedule procurement, Krungthai Axa wellness-bundle 2026

FY2026 premium pricing
THB 24,000-58,000 annual (CGM, Oura Ring, Apple Watch subsidy bundled)

Krungthai Axa Wellness Bundle Premium Tier Annual Premium

Krungthai-AXA wellness-bundle 2026 product disclosure, Insight derivation from Bangkok Insurance and Dhipaya wellness tier announcements

Report context

Thailand CGM & Wearable Health Tracker 2027 Market Intelligence

Thailand has 5.2 million diagnosed diabetics and 8.7 million pre-diabetes (HbA1c 5.7 to 6.4 percent), with continuous glucose monitor (CGM) adoption (Abbott FreeStyle Libre 3, Dexcom G7, Medtronic Guardian Sensor 4, Roche Accu-Chek SmartGuide) and downstream consumer wearable health-tracker uptake (Oura Ring Gen4, Whoop, Apple Watch, Samsung Galaxy Watch, Huawei Watch D, Garmin Venu) compounding across 2026 to 2027. The 2026 to 2027 catalyst stack includes the NHSO Universal Coverage benefit-schedule bundling of CGM for Type-1 diabetics and gestational diabetes pregnancies (~80,000 to 130,000 reimbursed units) effective Q3 2026; the Thai FDA Q1 2026 over-the-counter reclassification of CGM sensors from Class III prescription-only to Class II pharmacist-counseling status, dropping sensor average selling price from THB 4,800 to 6,500 to THB 1,950 to 2,800; the Krungthai Axa, Bangkok Insurance and Dhipaya wellness-bundle premium tiers covering CGM, Oura Ring and Apple Watch; the Thai metabolic-health interpretation software layer (BeYou by Khon Kaen University, Glucose Goddess Thailand, Vata); the BOI Section 8 medical-device incentive plus corporate income tax deduction for employer-provided wearable wellness benefits; and the Apple, Samsung, Huawei consumer non-invasive glucose research pipeline approaching clinical accuracy by 2027 to 2028. Our read: the 2027 Thai CGM and consumer wearable health-tracker market reaches THB 9 to 15 billion (vs THB 1.4 to 2.3 billion in 2024), with Abbott, Dexcom, Medtronic, Apple, Samsung, Oura, Whoop and Garmin capturing roughly 80 percent share and Thai interpretation-layer brands (BeYou, Glucose Goddess Thailand) plus a parallel-import long tail capturing the remainder.

Open report →

Atlas actors in this figure's reports

Profiles covered in the report that cite this number.

Abbott Thailand

US-parent MNC diagnostics, CGM, nutrition, cardiovascular; FreeStyle Libre anchor; ~6% Thai medical-device market share.

Medtronic Thailand

Ireland-HQ global MNC surgical, cardiac, diabetes, neurology leader; ~9% Thai medical-device market share.

Thailand Diabetes and Pre-Diabetes Prevalence · Insight